Organic & Biomolecular Chemistry · 2011 · 63 citations · 28 references
MedicineNeurosciencePharmacologyDrug DiscoveryMolecular ImagingMolecular NeuroscienceAlzheimer DiseaseAmyloid FormationBlood-brain Barrier PharmacologyLigand BindingMolecular Probe DevelopmentNanomedicineAmyloid Beta PeptidesAmyloid Fibril FormationAmyloid FibrilsAmyloid StructureBioluminescent ProbesBlood-brain Barrier PermeabilityFluorescent ProbesQuinoxaline Chemistry
Here we describe the identification and preliminary characterization of a new class of pyrrolo(imidazo)quinoxaline hydrazones as florescent probes for Aβ(1-42) fibrils. All the newly developed compounds were able to bind amyloid fibrils formed in vitro and some of them displayed an increase of their fluorescence upon binding. When tested on brain tissue preparations presenting Aβ deposits, the described hydrazones selectively stained amyloid structures and did not display aspecific binding. The hydrazones did not show antifibrillogenic activity and electron microscopy analysis revealed that they do not interfere with fibrils structure. The described pyrrolo(imidazo)quinoxalines could be useful for studying amyloid structures in vitro. Moreover, their experimentally proven ability to cross the blood-brain barrier in mouse opens the possibility of developing these compounds as potential amyloid imaging agents for in vivo applications.
28
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
William E. Klunk, Henry Engler, Agneta Nordberg et al. · Annals of Neurology · 2004 · 4.5K citations
Medicine, Neurology, Neuroscience +15
M. Azhar Chishti, Dun-Shen Yang, Christopher Janus et al. · Journal of Biological Chemistry · 2001 · 954 citations · Full text